Upper Tract Urothelial Carcinoma VL

Contemporary Trends of Systemic Neoadjuvant and Adjuvant Intravesical Chemo for UTUC - Francesco Del Giudice & Ben Chung

Details
Francesco Del Giudice and Ben Chung join Sam Chang in a discussion on addressing the contemporary trends of systemic neoadjuvant and adjuvant intravesical chemotherapy for upper tract urothelial carcinomas undergoing minimally invasive or open radical nephroureterectomy focused on a large insurance claim dataset from the United States. In this conversation, Francesco Del Giudice, and Ben Chung spe...

Practice Changing Abstracts in Upper Tract Urothelial Carcinoma, A Review from the 2022 AUA - Firas Petros

Details
Firas Petros, Urologic Oncologist from the University of Toledo College of Medicine joins Sam Chang in reviewing practice-changing and hypothesis-generating abstracts from the upper tract urothelial carcinoma podium session at the 2022 Annual Meeting of the American Urological Association (AUA). Dr. Petros first highlights two abstracts that involved the use of circulating tumor DNA as a biomarker...

A Multidisciplinary Approach to Treating High-Grade Upper Tract Disease - A Case-Based Approach - Surena Matin, Jonathan Coleman, and Jean Hoffman-Censits

Details
Surena Matin, Jonathan Coleman, and Jean Hoffman-Censits join Sam Chang in a case-based discussion on approaches to the treatment of upper tract disease. The group evaluate a 75 years old, former smoker, who develops painless gross hematuria. His CT shows a 3-centimeter, left upper pole filling defect with a soft tissue mass. Labs are essentially normal. GFR is 65. The patient has good performance...

Antegrade Administration of Reverse Thermal Mitomycin Gel for Primary Chemoablation of Upper Tract Urothelial Carcinoma via Percutaneous Nephrostomy Tube - Katie Murray

Details
Katie Murray joins Alicia Morgans to discuss reverse thermal mitomycin (JEMLYTO®) for primary chemoablation of upper tract urothelial carcinoma (UTUC) via a percutaneous nephrostomy tube. Based on results from the pivotal OLYMPUS trial, JELMYTO® is currently approved for low-grade UTUC. Dr. Murray speaks to two different methods of administration of the mitomycin gel that was allowed in this trial...

Evaluating the Impact of Variant Histology Pathologic Diagnosis on Survival Outcomes in Patients with Upper Tract Urothelial Carcinoma - Wesley Yip

Details
Wesley Yip joins Sam Chang in discussing variant histologies in the diagnosis of upper tract urothelial carcinoma. There are some unique challenges in managing upper tract urothelial carcinoma, and there still is a persistent need to define the impact of variant histology in the upper tract on patient outcomes to affect disease management, adjuvant therapies, and follow-up strategy. The purpose of...

Upper Tract Urothelial Carcinoma Highlights - Nima Almassi

Details
Nima Almassi joins Sam Chang to discuss some exciting abstract highlights about upper tract urothelial carcinoma presented at the AUA 2022. Dr. Almassi shares key takeaways on studies regarding nephron-sparing treatments for upper tract disease. He also discusses research on the increasing administration of intracavitary or topical treatment. The pair also discuss new developments in the field, in...

Adjuvant Therapy after Nephroureterectomy for High-Risk Upper Tract Urothelial Carcinoma - Sima Porten

Details
In this conversation, Sam Chang invites Sima Porten to highlight her 2022 AUA presentation, part of the Society of Urologic Oncology (SUO) session where she presented on Adjuvant Therapy after Nephroureterectomy for High-Risk Upper Tract Urothelial Carcinoma (UTUC). Drs. Porten and Chang and Dr. Porten discuss risk stratification in UTUC, immunotherapy as a treatment option now in the adjuvant set...

Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101 in the OLYMPUS Trial - John Gore

Details
In this discussion with Sam Chang, John Gore reviews an updated analysis of the OLYMPUS trial analyzing the durability or 12-month effectiveness of patients that had a complete response to MitoGel. The OLYMPUS trial evaluated the long-term safety and durability of response to UGN-101, a mitomycin-containing reverse thermal gel, (MitoGel) as primary chemoablative treatment for low-grade upper tract...

Comparative Effectiveness Of Neoadjuvant Chemotherapy In Bladder And Upper Urinary Tract Urothelial Carcinoma - Jeffrey Holzbeierlein

Details
Sam Chang and Jeffrey Holzbeierlein discuss the comparative effectiveness of neoadjuvant chemotherapy for bladder cancer, as well as for upper urinary tract urothelial carcinoma. Dr. Holzbeierlein goes into depth on the background of neoadjuvant treatment for these diseases, as well as a look at the POUT trial. They also discuss future projects and exciting new studies. Biographies: Jeffrey Holzbe...

Preventing Recurrence of Urothelial Carcinoma in Patients with Upper Tract Carcinoma - Aditya Bagrodia

Details
In this discussion with Sam Chang on the prevention of bladder recurrence, Aditya Bagrodia starts off with a case study of a 69-year-old female in generally good health, presents with hematuria, well-controlled diabetes, hypertension, remote history of smoking, and importantly, no history of upper tract urothelial cancer in the family or other Lynch syndrome-associated malignancies. Drs. Bagrodia...
email news signup